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available evidence on diagnosis and management of these disorders has been
published for the first time. The article received considerable attention, illus-
trating the importance of an expert panel to evaluate and compile recommen-
dations to guide rare disease patient care. Since that time, a growing body of
evidence on transplant outcomes in MMA and PA patients and use of precur-
sor free amino acid mixtures allows for updates of the guidelines. In this arti-
cle, we aim to incorporate this newly published knowledge and provide a
revised version of the guidelines. The analysis was performed by a panel of
multidisciplinary health care experts, who followed an updated guideline
development methodology (GRADE). Hence, the full body of evidence up until
autumn 2019 was re-evaluated, analysed and graded. As a result, 21 updated
recommendations were compiled in a more concise paper with a focus on the
existing evidence to enable well-informed decisions in the context of MMA and
PA patient care.
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1 | INTRODUCTION
The first guidelines on isolated methylmalonic acidaemia
(MMA) and propionic acidaemia (PA) were published in
September 2014 and accessed over 53 000 times on the
journal's website and cited 182 times according to Web of
Science (July 2020).1 The attention the guidelines
received signifies the interest and utilisation by health
care professionals of this evidence evaluation and
deduced recommendations as provided by an expert
panel. Especially in the rare disease field, structured eval-
uation of the present evidence is of great value, as the
process involves specific considerations related to the rar-
ity of these types of disorders. High-quality trials in large
samples which would produce firm and reliable evidence
are scarce given the small patient populations, often ren-
dering the present evidence low quality. As a result, evi-
dence collected from case series or smaller studies needs
to be carefully evaluated.
The advances in the field and the success of the first
MMA/PA guidelines prompted us to provide an update
6 years later. The guidelines presented here use a differ-
ent and more up-to-date system to evaluate evidence than
the first version, the ‘Grading of Recommendations,
Assessment, Development and Evaluation’ (GRADE)
approach,2 which is more suitable for the rare disease
field, as it partially accounts for the above described chal-
lenges. Due to the change of methods, the whole body of
literature on MMA and PA referenced on PubMed
(https://pubmed.ncbi.nlm.nih.gov/) was newly evaluated.
Since the publication of the initial guidelines, new
advances have been made, and more data have been pub-
lished on MMA and PA. For example, more patients have
been organ transplanted and their outcomes were publi-
shed. Several novel studies investigated the impact of
using precursor free amino acids (PFAAs) as part of the
dietary regimen of MMA and PA patients. The updated
guidelines presented here aim to include this new data,
while at the same time attempt to streamline and sum-
marise sections for which the evidence has not signifi-
cantly changed. The reader is provided with the full
recommendations for MMA and PA diagnosis and man-
agement but is referred to the initial guidelines for more
details regarding certain aspects.
This first revision of the MMA and PA guidelines
covers the same subtypes of isolated MMA and PA as
before. MMA is caused by a deficiency of the met-
hylmalonyl-CoA mutase enzyme (MMUT), either by a
direct defect of the enzyme, or by a deficient synthesis of
its cofactor adenosylcobalamin. Precursors of this path-
way are derived from specific amino acids (valine,
Synopsis
Structured evidence evaluation of the pre-
sent literature resulted in 21 recommenda-
tions on how to diagnose and manage
patients with methylmalonic acidaemia
and propionic acidaemia.
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isoleucine, threonine, methionine), propionate produced
by gut bacteria and odd chain fatty acids as well as the
cholesterol side chain (Figure 1). Under isolated MMA,
the following gene defects are included: deficiencies of
MMUT (OMIM #251000), MMAA (OMIM #251100),
MMAB (OMIM #251110) and truncating mutations
towards the N-terminal in the MMADHC gene (OMIM
#277410).3 PA (OMIM #606054) is caused by mutations
in the PCCA (OMIM #232000) or PCCB gene (OMIM
#232050), resulting in deficiency of the propionyl-CoA
carboxylase enzyme function.4
2 | METHODOLOGY AND
OBJECTIVES
The presented revision of the guidelines for MMA and
PA was undertaken by a panel of 21 health care profes-
sionals who work in the field of metabolic medicine. P. F.
(secretary), M. R. B., F. H. (co-chairs) and M. Huemer
(methodology and moderation) formed a core panellist
group to coordinate organisational and content aspects.
The panel further included paediatric metabolic
specialists (D. B., A. C., K. A. C., C. D.-V., S. C. G., S. G.,
T. H., D. K., S. S.-B., G. T., M. W.), a metabolic adult phy-
sician (M. Hochuli), a paediatric metabolic dietitian
(M. D.), paediatric neurologists (G. H., D. M.), a medical
doctor in training and PhD student in inherited meta-
bolic diseases (F. M.) and a clinical biochemist (J. O. S.).
The panel was supported by external reviewers for review
of nephrology, cardiology, neurology and dietetic recom-
mendations and two patient representatives. The panel
met in person in September 2019 and November 2019).
2.1 | Literature search and evidence
grading
In the initial guidelines, the method to collect the evi-
dence was based on SIGN.5 In the revised guidelines, the
GRADE methodology was used.
To gather the initial evidence base, a PubMed search was
performed on September 29, 2019 with the following search
term: (“propionic acidemia” OR “propionic acidaemia” OR
“propionic aciduria” OR “methylmalonic acidemia” OR
“methylmalonic acidaemia” OR “methylmalonic aciduria”
FIGURE 1 Propionyl-CoA is
metabolised in the mitochondria by
specific enzymes. Defects in the genes
MMUT, MMAA, MMAB or MMADHC
(more specifically variant 2) lead to
isolated MMA, whereas defects in PCCA
or PCCB lead to PA. Propionyl-CoA is
derived from various sources and is
metabolised to alternative products in
the case of accumulation in the above-
described defects. In addition,
accumulating methylmalonyl-CoA in
isolated MMA is hydrolysed to
methylmalonic acid, the main biomarker
of this disease. Gene names are
italicised, complementation groups are
in parenthesis. MMA, methylmalonic
acidaemia; PA, propionic acidaemia
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OR “propionic acidemias” OR “propionic acidaemias” OR
“propionic acidurias” OR “methylmalonic acidemias” OR
“methylmalonic acidaemias” OR “methylmalonic acidurias”)
AND (“"1900/01/01"[Date - Publication]: "2019/09/05"[Date
- Publication]) AND (english[Language]) NOT (animals[mh]
NOT humans[mh]). This search yielded 1488 entries. Articles
were manually sorted to 194 clinical reports on patients with
MMA and/or PA (any lab-based studies and case reports
with less than three patients excluded) that were stratified
into categories (P. F., M. B.) (Figure S1). Case reports were
considered in bulk for specific questions. Eight articles publi-
shed past the cut-off date and seven articles cited within the
initial clinical reports were considered by the panel to be of
specific importance (total of 209 articles). Articles were allo-
cated to the categories ‘high’, ‘moderate’ and ‘low’ quality of
evidence to a certain outcome by at least two panellists.
2.2 | Development process
In a first face-to-face meeting, panellists were informed
about and received guidance on how to apply the
GRADE methodology.
The panellists agreed that the guidelines should
address all types of isolated MMA and PA in patients of
all ages. Panellists and patient representatives selected
and rated outcome parameters as critical, important, or
not important using an online tool. The literature was
assigned to the critical and important outcomes and dis-
cussed and evaluated in working groups (email or
online/phone meetings), which formulated first drafts for
recommendations. A consensus-oriented, moderated dis-
cussion of the evidence and wording of the recommenda-
tions was held during the second face-to-face meeting.
Based on this meeting, the evidence profile was created,
and recommendations were formulated. Since during the
COVID-19 pandemic personal in-person meetings were
impossible, the panellists rated the quality of the evi-
dence for each outcome using an online tool. Final rating
of the quality of evidence was based on at least 50% of
votes for the category ‘high’, ‘moderate’ or ‘low’. If two
categories received equal numbers of votes, the quality of
the evidence was downgraded to the lower category
(Figure S2A).
The strength of each recommendation was finally
rated by the panellists based on the quality of the
FIGURE 2 Scheme depicting the extra- and intracellular transport and processing of the cobalamin (Cbl) molecule and the involved
proteins. Methylmalonyl-CoA mutase (MMUT), methylmalonic aciduria type A protein (MMAA), methylmalonic aciduria type B protein
(MMAB), methylmalonic aciduria and homocystinuria type D protein variant 2 (MMADHC-MMA), and propionyl-CoA carboxylase (PCC)
defects and their related diseases are discussed in these guidelines, hence these proteins are depicted in bold print. The other proteins are
depicted using official protein nomenclature: amnionless (AMN) and cubulin (CUBN) form the cubam receptor to absorb cobalamin bound
to cobalamin binding intrinsic factor (CBLIF); haptocorrin (TCN1; not shown), transcobalamin (TCN2) and transcobalamin receptor
(CD320) facilitate cobalamin transport and uptake into the cell; lysosomal cobalamin transporter (ABCD4) and lysosomal cobalamin
transport escort protein (LMBD1) export cobalamin from the lysosome; methylmalonic aciduria and homocystinuria type C protein
(MMACHC) cleaves the R group of cobalamin (upper-axial ligand); methylmalonic aciduria and homocystinuria type D protein (MMADHC)
targets cobalamin towards further processing in the cytosol or the mitochondrion; methionine synthase (MS), kept in its active form by
methionine synthase reductase (MSR), uses cobalamin in its methylated form; methylmalonyl-CoA epimerase (MCEE) converts (R)-
methylmalonyl-CoA to (S)-methylmalonyl-CoA; succinyl-CoA synthetase (SCS) also called succinate-CoA ligase forms succinate from
succinyl-CoA in the citric acid cycle
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evidence as well as the balance of benefits and harms,
values, preferences and resources. Recommendations
were downgraded to the lower category (weak) if the dis-
tribution of votes was exactly equal (Figure S2B).
Strong recommendations are indicated by ‘we recom-
mend’; weak recommendations by ‘we suggest’. Some
recommendations were considered extremely well based
on clinical grounds or would have serious consequences
if not followed; others were clearly supported by bio-
chemical facts and well-established medical knowledge.
In these cases, the wording of the recommendation was
strengthened (‘we strongly recommend’). For approval
ratings for each recommendation, see Figure S3.
2.3 | Guidelines objective
The purpose of these guidelines is to serve health care
professionals working with MMA and PA patients as an
evidence-based reference to provide optimal patient care.
When clear-cut recommendations could not be reached
because of poor evidence quality, the presented collation
of the body of the evidence may serve as a reference,
when considering specific aspects of MMA and PA
patient care. However, the guidelines do not replace com-
prehensive clinical reflection and assessment of each
patient's individual situation. These guidelines attempt to
provide guidance where there is sufficient evidence,
while at the same time identifying knowledge gaps in the
evidence.
3 | GUIDELINES
3.1 | Outcome parameters
An outcome parameter reflects a specific entity by which
a patient suffering from MMA or PA can be affected. This
can be a clinical sign (eg, kidney dysfunction or cardio-
myopathy) or a complex mix of several factors [eg,
health-related quality of life (HrQoL) or metabolic stabil-
ity]. Eleven outcome parameters were initially proposed
by the core panellist group. After a round of open feed-
back from the panel and the patient representatives, four
further outcomes were added. The importance of the dif-
ferent outcomes was gradually rated from 1 (of lowest
importance) to 9 (most critical for decision-making)
(Table 1). Survival was the most highly rated outcome
parameter, followed by HrQoL and metabolic stability.
The lowest rated outcomes were haematological abnor-
malities and bone health. Importantly, none of the out-
comes were underestimated by the panel when compared
to the patient representatives' ratings (Figure S4).
The following recommendations are structured
according to a patient's natural pathway from initial pre-
sentation and diagnostic procedures to management,
long-term complications and monitoring. The above-
defined outcomes guide this path and each of the recom-
mendations directly refers to an outcome.
3.2 | Diagnostic challenges
3.2.1 | Clinical presentation
A patient can only be diagnosed with MMA or PA when
the physician recognises the clinical picture suggestive of
MMA or PA, which can be a challenging process as many
of the clinical signs are non-specific. MMA and PA can
present with acute, chronic or intermittent symptoms,
which can often aggravate or even occur for the first time
following a ‘trigger’ event. Symptoms include vomiting,
weight loss, hypoglycaemia, neurological deterioration
with hypotonia, irritability and lethargy eventually lead-
ing to coma in the case of an acute early onset neonatal
presentation. This clinical presentation can be accompa-
nied by the biochemical findings of metabolic acidosis,
ketosis, hyperlactataemia and hyperammonaemia. Trig-
gers of an acute episode include but are not limited to
post-partum neonatal stress and other forms of catabolic
FIGURE 3 Proposed
management flowchart for
MMA and PA patients during an
acute metabolic
decompensation, based on
expert opinion. All drugs are
given intravenously (IV). MMA,
methylmalonic acidaemia; PA,
propionic acidaemia
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states induced by infection or prolonged fasting. Late-onset
patients present with a wider range of signs, involving fail-
ure to thrive, a range of neurological symptoms (encepha-
lopathy, developmental delay), cardiac and kidney
manifestations. We provide a slightly updated table of main
and rare signs and symptoms occurring during acute or
chronic presentation of MMA or PA (Table 2).
Recommendation #1. We strongly recommend consid-
ering MMA and PA in the differential diagnosis of
an acute or intermittent neurological deterioration,
and in the differential diagnosis of neonatal sepsis.
Outcome: Survival.
Quality of evidence: moderate.
Strength of recommendation: very strong (supported
by medical knowledge).
3.2.2 | Laboratory diagnosis
When, based on clinical assessment and basic laboratory
parameters or on an abnormal result from newborn
screening, an organic acidaemia is suspected, the diagno-
sis of MMA or PA is achieved by measurements of
organic acids in urine (Table 3). Elevations of
methylmalonic acid together with 3-hydroxypropionate
and presence of 2-methylcitrate confirm a diagnosis of
MMA, while the same pattern without abnormal levels of
methylmalonic acid is present in PA. Often, tiglylglycine
and propionylglycine can be found in PA. The diagnostic
work-up may be complemented with the measurement of
acylcarnitines in dried blood spots or plasma. In this test,
a striking elevation of C3 acylcarnitine (pro-
pionylcarnitine) can be found in both MMA and PA. In
addition, plasma amino acid measurements show ele-
vated glycine levels in MMA and PA.
Recommendation #2. We strongly recommend mea-
surement of organic acids in urine to achieve a reli-
able diagnosis of MMA or PA.
Outcome: Early diagnosis.
Quality of evidence: high.
Strength of recommendation: very strong (supported
by biochemical knowledge).
3.2.3 | Differential diagnosis
As illustrated (Figure 1), the methylmalonyl-CoA mutase
enzyme can be dysfunctional due to several different
genetic defects, all of which lead to an elevated level of
methylmalonic acid in urine and in blood. The differen-
tial diagnosis of raised methylmalonic acid entails a
range of diseases. Specifically, methylmalonic acid can be
raised due to a defect in MMUT or one of the genes distal
in the intracellular cobalamin pathway, causing the
MMA subtypes discussed in these guidelines, or due
defects more proximal in the intracellular cobalamin
pathway as well as nutritional deficiency of cobalamin.
To differentiate the diseases discussed in these guidelines
from the more proximal ones and impaired cobalamin
supply, homocysteine and vitamin B12 levels in blood
should be measured, which are expected to be normal in
isolated MMA (except in the case of incidental concomi-
tant nutritional vitamin B12 deficiency in isolated
MMA). The magnitude of methylmalonic acid elevation
can further help the classification of the different defects
in the pathway3 (Table 3). In addition, other rare genetic
defects lead to an isolated, albeit milder elevation of met-
hylmalonic acid with normal homocysteine but are not
part of these guidelines. These genes include MCEE,
encoding methylmalonyl-CoA epimerase, and SUCLG1,
SUCLA2, which encode succinate-CoA ligase, and others
(Figure 2). MCEE deficiency can in very rare cases pre-
sent with an acute metabolic decompensation, but is
clearly clinically less severe compared to isolated MMA.7
TABLE 1 Outcome parameters and their ratings of importance
Outcome parameter



















Note: Each outcome parameter was rated by the panellists and the patient
representatives from 0 (lowest importance) to 9 (most critical for decision-
making). The second column represents the median value of all the ratings.
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As the propionyl-CoA carboxylase enzyme requires
biotin as a cofactor, nutritional biotin deficiency or a
defect of the enzymes biotinidase (BTD gene, OMIM
#609019) or holocarboxylase synthetase (HLCS gene,
OMIM #609018) must be excluded to finalise the diagno-
sis of PA. In all these cases, the urinary organic acid pro-
files would not only include elevated levels of the
metabolites pathognomonic for PA (3-hydroxypropionate
and 2-methylcitrate), but also other metabolites arising
from deficiencies of other biotin dependent carboxylases
such as methylcrotonylglycine.
Both MMA and PA are inherited in an autosomal
recessive fashion. To confirm the biochemical diagnosis,
guide management and allow genetic counselling of fam-
ilies, it is necessary to identify the underlying genetic
defect. Isolated MMA can be caused by defects in four
different genes, including MMUT (mut subtypes), MMAA
(cblA), MMAB (cblB), MMADHC (cblD-MMA).3 Specific
mutations in MMADHC can also lead to a combined phe-
notype of MMA and homocystinuria or isolated homo-
cystinuria.8 In the rare case of inconclusive genetic
results, complementation studies, the propionate
FIGURE 4 Proposed management
flowchart for MMA and PA patients undergoing
general anaesthesia, based on expert opinion.
MMA, methylmalonic acidaemia; PA, propionic
acidaemia
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incorporation assayor enzyme activity measurements in
fibroblasts can aid in the diagnostic process.3,9,10 Many of
the known MMUT mutations have been functionally
tested with the aforementioned assays, allowing the his-
toric classification as a mut0 subtype (no response to
hydroxocobalamin supplementation in the propionate
incorporation assay) or a mut− subtype (increased propio-
nate incorporation upon addition of hydroxocobalamin
to the cell culture medium).11,12
In the case of PA, there is no evidence that identifica-
tion of the underlying gene defect (in PCCA or PCCB)
can guide management or prognosis, as no genotype-phe-
notype correlation is known.13 However, molecular
genetic confirmation of the disease is useful for genetic
counselling and potential prenatal diagnosis.
Recommendation #3. We suggest molecular genetic
testing in any patient with a biochemical diagnosis
of MMA and PA for confirmation of the diagnosis,
allocation to subgroups (mut0, mut−, cblA, cblB,
cblD-MMA), genetic counselling, and to enable pre-
natal diagnosis.
Outcome: Early diagnosis.
Quality of evidence: moderate.
Strength of recommendation: weak.
3.2.4 | Prenatal testing
Prenatal diagnosis is preferentially performed by molecu-
lar analyses in foetal DNA. Biochemical analyses for
MMA or PA can be used as an alternative or additional
method in cases where the genetic results are inconclu-
sive or not available. Prenatal diagnosis of MMA can be
performed by measurement of MMA in dried amniotic
fluid14 and of PA by determination of 2-methylcitrate
with the same method.15 The combination of two inde-
pendent methods (biochemical and genetics) increases
the reliability of results.16 These guidelines only recom-
mend on the mode of prenatal diagnosis and do not
address individual, cultural and ethical values and
considerations.
Recommendation #4. We suggest using genetic testing
for prenatal diagnosis of MMA and PA.
Outcome: Early diagnosis.
Quality of evidence: moderate.
Strength of recommendation: weak.
3.2.5 | Newborn screening
Propionylcarnitine (C3) is a disease biomarker but can
display variable elevations in the context of newborn
screening for MMA and PA. From a methodological per-
spective sensitivity and specificity for diagnosis of MMA
and PA from dried blood spots, obtained during the first
days of life, can be optimised by measuring C3/C2 ratio,
2-methylcitrate,17-19 3-hydroxypropionate,20 C3/C0 and
C16:1OH/C221 and C17,22 either as part of the initial
screening or as second tier testing.
In more recent studies, newborn screening has been
shown to increase the chance of early diagnosis of MMA
and PA patients,23,24 especially in late-onset cases.25
While newborn screening may decrease neonatal mortal-
ity,26 it may not prevent neonatal metabolic decompensa-
tion, potentially due to the delay until the newborn
screening result is available. Additionally, newborn
screening may not improve important outcome parame-
ters, including metabolic stability and cognitive develop-
ment.23,27-30 In countries in which MMA and PA is not
part of newborn screening but the method is based on
obtaining a full acylcarnitine profile, immediate
‘unblinding’ of the profile in children with suggestive
TABLE 2 Potential signs and symptoms at presentation
observed in MMA and PA patients












Vomiting Recurrent vomiting with
ketoacidosis
Feeding difficulties Failure to thrive
Pancreatitis
Haematopoietic system
Neutropenia, pancytopenia Neutropenia, pancytopenia
Heart (mostly in PA)
Acute cardiac failure (mostly
based on cardiomyopathy)
Cardiomyopathy





Abbreviations: ECG, electrocardiogram; MMA, methylmalonic acidaemia;
PA, propionic acidaemia; QTc, corrected QT interval.
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clinical signs and symptoms can avoid significant diag-
nostic delay.
A minority of countries in the European Union (7/27)
performed newborn screening for MMA and PA in
2015.31 As the modality of screening, including confirma-
tory testing, is variable, and often structured follow-up
programs focussing on patient-relevant outcomes are
absent, systematic evaluation of MMA and PA newborn
screening programs is warranted in order to allow for a
general recommendation in favour or against MMA and
PA newborn screening in the future.
3.3 | Management of MMA and PA
3.3.1 | Initial treatment
Early diagnosis and timely treatment are essential to
improve survival and reduce morbidity in MMA and PA
patients. Over time survival of these patients has
improved.23,26,32-35 Improved survival seems to be due to
improved treatment strategies and patient monitoring.
The effect of single treatment variables on survival, how-
ever, is not clear from the present evidence. In MMA
patients, survival also depends on age of onset and dis-
ease subtype; early-onset MMA patients, in particular
mut0 and cblB patients, have a higher mortality risk.33,34
As soon as the diagnosis of MMA and PA is
suspected, specific therapies should be initiated and the
patient should be referred to a specialist centre as some
of the treatments and specialist knowledge are only avail-
able there.35 Intensive care treatment of patients with a
metabolic decompensation can be necessary if there is a
severe metabolic acidosis with or without
hyperammonaemia, and hyperlactataemia. The specifics
of these acute treatment modalities, including extracor-
poreal detoxification, have not been systematically stud-
ied yet, and the contribution of individual treatments to
the improved survival over the last decades is unclear.
The panel has intensively discussed the available evi-
dence and has come up with principles based on expert
opinions of how to approach treatment of an (imminent)
acute metabolic decompensation in MMA and PA
patients (Figure 3). It seems appropriate to advise against
the primary use of sodium phenylbutyrate as ammonia
scavenger in MMA and PA as it can lead to decreased
glutamine levels, potentially hampering tricarboxylic acid
cycle anaplerosis via 2-ketoglutarate.36 More recently,
carglumic acid was trialled as part of hyperammonaemia
treatment strategies in MMA and PA.37-39 While the med-
ication was so far tolerated with no side effects,40 further
systematic studies are required to prove its efficacy.41
Further, it has to be noted that extensive administration
of glucose intravenously can be associated with lactic aci-
dosis, potentially due to the inhibited pyruvate dehydro-
genase enzyme in MMA and PA.
It is not possible to make evidence-based statements
on improvement of survival with liver transplantation, as
the published studies focus on the survival shortly after
transplantation, but long-term comparisons to non-
transplanted patients are absent. This applies to liver,
kidney and liver-kidney transplantations, where overall
survival after surgery is around 85%.42-44
Recommendation #5. If the diagnosis of MMA or PA
is suspected, we suggest immediate specific treat-
ment to improve survival in MMA and PA.
Outcome: Survival.
Quality of evidence: moderate.
Strength of recommendation: weak.
3.3.2 | Metabolic stability
The term metabolic stability is often used in the clinical
context, but its meaning is seldom stated explicitly. For
the purpose of these guidelines, we defined metabolic sta-
bility as the absence of hospitalisation and exacerbation
of disease signs and symptoms, especially metabolic aci-
dosis and hyperammonaemia. Per this definition meta-
bolic stability is a complex term, as it is influenced by
various factors, some of which are addressed in this
chapter.
Levels of biochemical metabolites, such as met-
hylmalonic acid, propionylcarnitine and plasma amino
acids, are often used as surrogate markers for metabolic
stability (refer to the ‘monitoring’ section for details on
measurement frequencies). The present evidence,
though, suggests to rely on clinical assessment, including
review of medical history, and the measurement of sim-
ple biochemical parameters, such as acid-base balance
(decreased pH and base excess, raised anion gap), urinary
ketones and plasma ammonia in the acute setting to dis-
criminate between a metabolically stable or a
decompensating situation.45,46 More recently, measure-
ment of fibroblast growth factor 21 (FGF21) and of 2-
methylcitrate showed potential to predict the develop-
ment of long-term complications.47-49
Trigger events leading to metabolic decompensation
include infections, causing fever and catabolism. Simi-
larly, prolonged fasting periods are leading to catabolism
and should be avoided to prevent metabolic instability.50
In such situations of a mild intermittent illness, it is com-
mon practice to apply enteral emergency feeds consisting
of a glucose polymer solution (occasionally with fat
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emulsion) to provide adequate energy and meet raised meta-
bolic demands. The emergency feeds should only be given
during a limited time and if they are tolerated, that is,
absence of vomiting and diarrhoea. In parallel, protein
intake (including PFAA mixtures) is stopped or partly
reduced, for example, to 50%, depending on the severity of
clinical symptoms. A simplified overview of age-dependent
emergency regimens based on glucose polymer solution is
provided (Table 4). Similarly, general anaesthesia requires
specific considerations to ensure adequate energy supply
and metabolic stability (Figure 4). As vaccinations do not
seem to trigger decompensation themselves, as demon-
strated in urea cycle disorders,51 regular vaccination proto-
cols are indicated for MMA and PA patients. Pregnancies
have been described in a few cases of MMA and PA without
metabolic decompensations.52-54
Generally, it is unclear whether resting energy expen-
diture in MMA and PA is abnormal.55-58 There is no evi-
dence in MMA and PA, but it may be considered, that
energy requirements might be lower in patients after a
metabolic stroke with subsequent reduced mobility.
Implementation of tube feeding can ensure adequate
nutrition and energy intake in a selected group of MMA
and PA patients.59,60
Further, the role of upcoming therapies, such as
mRNA therapy or other gene therapy approaches, on
metabolic stability and other outcome parameters will
need to be defined.61-65
Recommendation #6. We recommend avoiding cata-
bolic metabolism in MMA and PA patients to
improve metabolic stability.
Outcome: Metabolic stability.
Quality of evidence: moderate.
Strength of recommendation: strong (supported by
experience-based medical knowledge).
More dietary aspects are also described in the section
on normal growth. In general, a diet low in natural pro-
tein aims at the reduction of precursor molecules
funnelling into the defective pathway in MMA and PA.
Current practice of dietary management of MMA and PA
patients aims at both metabolic stability and normal
growth. It is based on adequate energy supply, avoidance
of prolonged fasting and reduced intake of precursor
amino acids (methionine, threonine, valine, isoleucine)
through a diet restricted in natural protein, and an ade-
quate provision of vitamins, minerals and trace minerals
and essential fatty acids for age. The amount of natural
protein must be assessed individually and must be based
on clinical and biochemical monitoring. Breastfeeding is
possible considering the total natural protein intake.
However, there is insufficient data to define a detailed
evidence-based dietetic strategy in MMA and PA.
Recommendation #7. We suggest a low natural protein
diet under consideration of age-appropriate total
protein requirements to improve metabolic
stability.
Outcome: Metabolic stability.
Quality of evidence: low.
Strength of recommendation: weak.
The following specific medications are also used to
facilitate metabolic stability. Levocarnitine treatment –
usually at a dose of 100 mg/kg/day – is applied with the
rationale of restoring depleted to normal carnitine and
CoA levels in MMA and PA patients, and based on its
ability to bind and eliminate propionyl-CoA molecules,
which are assumed to be responsible for some of the toxic
metabolite effects in MMA and PA.66 At least in PA,
levocarnitine might be able to improve metabolic stability
and help avoiding hyperammonaemic crises.36
Levocarnitine is considered a well-tolerated medication
with few side effects. A recent study shows elevated
plasma levels of trimethylamine N-oxide in MMA and
PA patients on levocarnitine treatment. Whether this
finding is related to an increased risk for cardiovascular
disease in MMA and PA patients on levocarnitine medi-
cation remains yet to be determined.67
TABLE 4 Emergency regimens
Age (years)
Glucose polymer concentration
(% carbohydrate) Fat emulsion (% fat)a
Energy (kcal per 100 mL
from carbohydrates and fat)
0-1 10 3.5 71.5
1-2 15 5 105
2-9 20 5 125
>10 25 5 145
Note: The amount of the glucose polymer solution should be determined according to age-adequate total daily fluid intake.
aFat emulsion can be added if expected to be well tolerated.
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Metronidazole – at 10 to 20 mg/kg/day in two to three
doses – has been part of the standard long-term manage-
ment to reduce bacterial propionate production in the
gut despite low quality of evidence for a benefit. There is
no evidence demonstrating neuropathy as an intrinsic
long-term complication in MMA or PA, but peripheral
neuropathy has been observed in PA patients under met-
ronidazole treatment68 and metronidazole is a known
cause of peripheral neuropathy.69,70 Other side effects
include QTc prolongation and pancreatitis; hence, metro-
nidazole treatment should be cautiously indicated in
MMA and PA patients. If metronidazole is not
well tolerated, alternative antibiotics, including amoxicil-
lin or cotrimoxazole, have been applied.
Whether carglumic acid can consistently reduce the
number of metabolic decompensations needs to be fur-
ther studied.71 It has been tried to anapleurotically sup-
port Krebs cycle function by providing citrate, which was
associated with reduced number of hospitalisations in
three PA patients.72
Recommendation #8. We suggest supplementation
with levocarnitine to improve metabolic stability.
Outcome: Metabolic stability.
Quality of evidence: low.
Strength of recommendation: weak.
Some MMA patients clearly benefit from parenteral
cobalamin treatment. Patients with cblA will mostly
improve, and cblB have been described to respond in one
third of the cases.73 Among the MMUT-deficient patients,
the mut− subgroup is more likely to show benefits from
cobalamin injections33 although clear evidence of cobala-
min responsiveness in mut− patients is lacking. The ideal
application route is intramuscular and hydroxocobalamin
is the preferred form of the cobalamin molecule. A proto-
col to evaluate biochemical responsiveness has been pro-
posed previously3: (a) The patient should be
metabolically stable without recent treatment changes.
(b) The patient should be off hydroxocobalamin supple-
mentation for at least 1 month prior to assessment. (c)
Collect at least three baseline urine or plasma (use the
same body fluid throughout) samples on different days
for measurement of methylmalonic acid. (d) Inject 1 mg
hydroxocobalamin intramuscularly on three consecutive
days. (e) Collect urine or plasma samples over 10 days,
every other day. (f) A mean decrease of urine or plasma
methylmalonic acid concentration of >50% is regarded
as a significant response. A similar cofactor treatment
with biotin for PA patients is not recommended, as
there has been no description of responsive patients
so far.
Recommendation #9. We recommend evaluating
responsiveness for parenteral vitamin B12 in every
patient with suspected MMA.
Outcome: Metabolic stability.
Quality of evidence: moderate.
Strength of recommendation: strong (supported by
basic biochemical knowledge).
Liver transplantation in MMA or PA and combined
liver-kidney as well as kidney transplantation in MMA
has been performed in several patients to improve the
disease outcome. Despite many transplanted patients, it
is difficult to provide detailed recommendations on this
topic. The lack of detailed follow-up studies and natural
history data leads to incomplete evidence for many of the
relevant outcome parameters. For the purpose of these
guidelines, we have investigated all articles of our litera-
ture search with regards to the patients who underwent
organ transplantation. We have identified nearly
300 MMA and PA patients, most of which were MMA
undergoing liver transplantation followed by PA patients
with the same procedure. It seems that MMA patients
increasingly receive a combined liver and kidney trans-
plant. Yap et al recently performed a similar analysis,
concluding that transplantation procedures in MMA and
PA patients have potential benefits as well as associated
risks.74 We suggest considering the management flow-
chart for MMA and PA patients undergoing general
anaesthesia provided in Figure 4, when performing any
transplantation procedure.
After liver and/or kidney transplantation, the number
of metabolic decompensations decreases and some report
a shortened hospital admission length during an inter-
mittent illness.42,54,75-103 Also biochemical markers (C3,
C3/C2 ratio, methylmalonic acid, 2-methylcitrate,
FGF21) seem to improve after transplanta-
tion.47,49,75,98,104 However, acute metabolic decompensa-
tions can still occur after transplantation in MMA and
PA patients and some of these decompensations have
been reported to be lethal.47,102,104-109 Therefore, follow-
up of any transplanted MMA or PA patient by a meta-
bolic clinician is indicated and regular metabolic moni-
toring seems to be essential.110 Organ transplantation of
patients in acute metabolic decompensation should be
avoided, as the procedure itself has the potential to cause
further decompensation.111
In transplanted MMA and PA patients diet
normalisation,42,84,89,90,93,94,103,104,112-115 liberalisation or
increased protein intake75,76,78,80,83,88,91,96-98,100,102,116-118
or continuation of dietary restrictions85,87,119 were all
applied following transplantation. Liberalised and contin-
uous diet both led to metabolically stable situations
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without acute decompensation.89,103 Other patients were
described to have metabolic acidosis post-transplant
while being on a continued protein restriction.86,102 Fur-
ther research is necessary to determine if continuation of
dietary restriction is necessary after transplantation. Until
the evidence is clearer further care by a metabolic spe-
cialist, including biochemical monitoring and regular die-
tetic review, as well as continuation of levocarnitine
seems appropriate.
It is of note, that the guideline panel did not
include transplantation surgeons and thus the avail-
able evidence was read from the perspective of meta-
bolic physicians. The panel suggests considering
patients for liver (MMA and PA) or combined liver-
kidney (MMA) transplantation who suffer from fre-
quent metabolic decompensations, as the strongest
effect of transplantations is the improvement of meta-
bolic stability.
Recommendation #10. We suggest considering liver
transplantation in MMA and PA, and combined
liver kidney transplantation in MMA to improve
metabolic stability.
Outcome: Metabolic stability.
Quality of evidence: low.
Strength of recommendation: weak.
3.4 | Long-term complications of MMA
and PA
With improved survival, long-term complications
become more apparent, including so far unknown
affections, such as liver neoplasms, namely hepato-
blastoma and hepatocellular carcinoma.120 It is essen-
tial to acknowledge that despite improved survival,
metabolic decompensations are still a major mortality
cause,34 and sudden death may occur due to prolonged
QT syndrome or cardiomyopathy.13,121,122 Detailed rec-
ommendations are provided according to specific out-
come parameters below.
3.4.1 | Neurological complications
A variety of neurological problems are associated with
MMA and PA disease. Due to their complexity, they are
split in separate sections according to the outcome
parameters cognitive development, metabolic stroke, epi-
lepsy, and vision and hearing impairment.
While some patient show stabilisation and even
improvement of neurological symptoms following organ
transplantation,80,88,98,99,117 it is essential to acknowledge
that after transplantation patients are still at risk of devel-
oping neurological complications. Cognitive development
often remains stable or improves post liver and liver-kid-
ney transplantation for MMA, and liver transplantation
for PA,44,80,81,86,87,92,97,104,105,115,123,124 but in one PA
patient cognitive abilities got worse post liver transplan-
tation.86 In both diseases, however, the available evidence
mostly lacks structured assessments of neu-
rodevelopmental outcome. Several (including severe)
new neurological sequelae occurred after liver, liver-kid-
ney and kidney transplantation in MMA and liver trans-
plantation in PA in up to 25% of patients. These included
onset of seizures, metabolic stroke,42,113 Leigh syn-
drome,44 worsening of vision and focal
leukoencephalopathy,125 generalised motor neuropathy85
and general neurological deterioration116 in MMA
patients; and metabolic stroke,86,104 epilepsy86 and tem-
poral mesial sclerosis126 in PA patients.
Cognitive development and psychiatric complications
Lack of natural history studies in terms of domain-spe-
cific outcomes and longitudinal developmental trajecto-
ries, different time points of evaluation, variety of patient
populations, use of non-standardised, variable test batte-
ries and cut-off values for normal development are
among the limitations to evaluate long-term cognitive
and psychiatric outcome of MMA and PA.
In MMA cobalamin non-responsiveness, early-onset
of disease, presence of hyperammonaemia or seizures at
onset and a mut0 subtype are associated with more
severe cognitive involvement, while all patients show
selective deficits in processing speed.33,127 In addition,
up to 20% of MMA patients are affected by neuropsychi-
atric problems.128,129 Other evidence illustrates the neg-
ative impact of the number of metabolic
decompensations on cognitive outcome, indicating that
improvement of metabolic stability might ameliorate
cognitive problems.130
On the other hand, PA seems to be generally associ-
ated with cognitive impairment, which in most studies
exceeds 50% of the evaluated patient popula-
tion.28,32,131-133 In addition, autism spectrum disorder,
anxiety and acute psychotic episodes are described.134-
139 The present evidence suggests, that early interven-
tion and treatment has little effect on the cognitive out-
come in PA.23
Recommendation #11. We suggest age-appropriate,
standardised developmental, cognitive and behav-
ioural testing, since developmental delay, intellec-
tual disability and/or behavioural abnormalities are
known complications in MMA and PA.
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Outcome: Cognitive development.
Quality of evidence: moderate.
Strength of recommendation: weak.
Metabolic stroke
The term metabolic stroke refers to the acute onset of a
central neurological deficit, often associated with a
decompensation of the underlying inborn error of metab-
olism, that cannot be accounted for by hypoxaemia or
vascular insufficiency.140 Metabolic strokes, particularly
involving the basal ganglia area, were reported in both
MMA and PA patients.28,126,141-145 They often occur dur-
ing an episode of metabolic decompensation or shortly
thereafter. In PA, several cases with metabolic stroke
without metabolic decompensation have been publi-
shed.143,146-150 Magnetic resonance imaging (MRI) can be
of help to diagnose a metabolic stroke and should be per-
formed based on clinical presentation and assessment.151-
153 One study precisely characterised globus pallidus
infarcts and developed a grading method to systemati-
cally assess the volume of the lesion.154 Movement disor-
ders are common in MMA and PA and may arise as a
consequence of a metabolic stroke event.33,131,155
There is no evidence for a specific management of meta-
bolic stroke. Therefore, standard symptomatic treatment
strategies for stroke in addition to the management of the
acute metabolic decompensation should apply. As described
above regarding the outcome of metabolic stability, liver
transplantation can improve metabolic stability and often
leads to the absence of metabolic decompensations,101 but
is unable to prevent metabolic strokes.113 In some patients,
brain MRI findings improved after transplantation87 while
also new MRI abnormalities without a clear metabolic
stroke have been reported after transplantation.102
Recommendation #12. We strongly recommend stan-
dard appropriate investigation for metabolic stroke,
if MMA or PA patients present with symptoms sus-
picious of a stroke-like episode.
Outcome: Metabolic stroke.
Quality of evidence: high.
Strength of recommendation: very strong.
Epilepsy
Epilepsy is a common complication in MMA (prevalence
of 23%-43% reported)33,155 and PA (prevalence of 25%-
59% reported).133,143,145,156,157 Seizures have even been
reported as the presenting symptom of the disease prior
to diagnosis in several cases of PA.143,146,148
There is no sufficient evidence to recommend a spe-
cific frequency of electroencephalogram recordings in the
absence of clinical symptoms of seizures. There is no
evidence to change standard epilepsy procedures and
treatment regimens in MMA and PA patients. Namely,
electroencephalogram evaluation should be performed in
the presence of any focal neurological symptoms or clini-
cally suspected seizures, and treatment with antiepileptic
drugs should be initiated accordingly. Caution is
warranted when valproic acid is used, as it can decrease
the concentration of levocarnitine by excretion of
valproylcarnitine.158
Recommendation #13. We strongly recommend moni-
toring symptoms of epilepsy in MMA and PA
patients as seizures are a common complication in
MMA and PA.
Outcome: Epilepsy.
Quality of evidence: moderate.
Strength of recommendation: very strong.
Vision and hearing
Optic neuropathy is one of the neurological long-term
complications of both MMA159-162 and PA13,28,159,163,164
occurring in infancy or later during the disease course,
affecting about 25% of patients. Onset of optic neuropa-
thy can be insidious and subclinical or acute.165,166
Sensorineural hearing loss seems to be less common
but was reported in several cases of MMA and PA
patients.23,28,122,162,163
Currently, there are no biomarkers or clinical signs
which would allow a prediction as to which patients will
develop visual or hearing impairment. Despite some
interesting pathophysiological considerations, which
mainly involve mitochondrial dysfunction,122 or interfer-
ence with potassium channels in the case of sensorineu-
ral deafness,167 no specific treatment can be
recommended for these complications.
Recommendation #14. We suggest monitoring of
visual and hearing function, since optic neuropathy
and sensorineural hearing loss are known compli-
cations in MMA and PA.
Outcome: Vision and hearing.
Quality of evidence: moderate.
Strength of recommendation: weak.
3.4.2 | Kidney dysfunction
Impaired kidney function is a well-documented long-
term complication in MMA and less frequent in
PA.32,34,122,156,162,168-172 Occurrence of kidney dysfunction
is related to the molecular subtype: mut0 patients are
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affected earlier in life than cblB patients; cblA and mut−
patients seem to be affected even later in life.32,33,122,173
Despite these differences it is thought that all patients
with isolated MMA are at risk of developing renal insuffi-
ciency in their long-term course of the disease.174
Although kidney disease in PA is only reported in single
cases, it can be severe, even requiring transplantation of
the dysfunctional organ.169
While the exact pathomechanisms remain unre-
solved, two pathological correlates in kidneys of MMA
patients have been described as tubulo-interstitial nephri-
tis and renal tubular acidosis.175-179 Mitochondrial
impairment seems to play a key role in the
pathomechanisms.122,180,181
Kidney growth is predicted by height and correlates
negatively with serum cystatin C and serum met-
hylmalonic acid concentrations.182 Estimation of glomer-
ular filtration rate (GFR) is more accurate using cystatin
C instead of the traditional creatinine, as it is indepen-
dent of muscle mass.4,182 As measuring GFR is a complex
procedure and often not available, we suggest using
cystatin C based estimated GFR. Regular blood pressure
monitoring should be part of kidney function assess-
ments. While FGF21 levels do not seem to correlate with
kidney function,48 plasma lipocalin-2 can be used as a
biomarker.172,180
There is no evidence allowing recommendations of
specific treatment strategies for kidney impairment or
failure in MMA and PA patients, hence, we suggest fol-
lowing standard protocols.
Recommendation #15. We strongly recommend moni-
toring of kidney function, as chronic kidney disease
is a complication in MMA and PA.
Outcome: Renal dysfunction.
Quality of evidence: high.
Strength of recommendation: very strong.
In MMA, combined liver and kidney transplantation
seems to be an efficient treatment of kidney failure,
resulting in good renal function, even up to 10 years after
transplantation.95,117,118,183,184 Kidney transplant
improves renal function shortly after transplantation and
in some even for years (1.5 years up to 14 years) after
transplantation,54,85,88,179 but recurrence of nephropathy
and renal failure has also been reported after kidney
transplant.47,185 After liver transplantation several
patients showed normal renal function even up to
15 years after transplantation,119,184 while others have or
develop (progressive) renal failure after transplanta-
tion.94,101,106,116,119 Liver transplantation seems not to
correct an already dysfunctional kidney.97
In PA, one patient was reported with kidney trans-
plant 17 years after liver transplant.91
In the context of transplantation, it has to be consid-
ered that calcineurin inhibitors can be nephrotoxic,
which was also found in MMA96,186 and PA patients.86
3.4.3 | Cardiac disease
Cardiomyopathy occurs in few MMA and in approxi-
mately 25% of PA patients.28,34,84,145,162,170,187,188 Cardio-
myopathy can present as an isolated clinical finding in
previously asymptomatic individuals.189,190 There does
not seem to be a correlation between the occurrence of
cardiomyopathy and metabolic stability, severity of the
phenotype or residual enzymatic activity.84 Cardiomyop-
athy can be rapidly progressive leading to cardiac failure
or even death.48
Long QT syndrome was reported in 22% and 33% of
PA patients in two large cohorts.28,162 Others observed an
even higher incidence of prolonged QTc interval (70%)
and arrhythmias (20%) in 10 PA patients with.191 Pro-
longed QTc and ventricular arrhythmias can result in
sudden cardiac arrest in PA patients.191,192
There is weak evidence that high doses of coenzyme
Q10 can improve cardiac function in PA patients with
cardiomyopathy.193 Beyond that, there is not enough evi-
dence to recommend any specific management of cardio-
myopathy or long QT syndrome in MMA and PA beyond
standard cardiac therapy.
Based on the above-described cardiac complications,
we suggest using electrocardiogram and echocardiogram
for regular monitoring (Table 5)
Recommendation #16. We strongly recommend regu-
lar cardiac examinations, since cardiomyopathy in
MMA and PA and long QT syndrome in PA are
potentially life-threatening complications.
Outcome: Cardiac disease.
Quality of evidence: high.
Strength of recommendation: very strong.
There are several reports showing stabilisation or
improvement of cardiomyopathy after liver transplanta-
tion.84,89,91,98,102,114,184,185,194 However, these results are
counterbalanced by studies illustrating the development
of cardiomyopathy and prolonged QTc after transplanta-
tion and reporting patients to have died as a consequence
of heart failure.91,105,188,195 Cardiac complications may at
least partly be attributed to medication and/or immuno-
suppressants used in the context of post-transplant treat-
ment, hence more systematic data of cardiac parameters
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and used medication must be collected to enable specific
recommendations regarding organ transplantation in the
context of cardiac outcome in MMA and PA. Potentially,
heart transplantation can be an option for PA patients
with isolated cardiomyopathy.196
3.4.4 | Haematological complications
Haematological abnormalities are common in MMA and
PA.122,162 Pancytopenia (especially neutropenia) at initial
presentation or during metabolic decompensation as well
as during the chronic disease course has been frequently
described.13,23,28,148,197-200 Isolated thrombocytopenia can
be observed during acute metabolic decompensa-
tions.13,23,28,148 Anaemia may rather present chronically
and depend on other factors such as the presence of
chronic kidney disease. Other postulated mechanisms
include reversible suppressive effects of toxic metabolites
on bone marrow function.198,201
Deficiencies of substrates for blood cell production
(vitamin B12, folic acid, iron) should be excluded in
patients with haematological abnormalities. Treatment of
anaemia with erythropoietin in patients with chronic kid-
ney disease should follow common nephrology standards.
Indication for treatment with granulocyte colony stimu-
lating factor is unclear, as there is very limited experience
in MMA and PA patients.13
Recommendation #17. We suggest monitoring of full
blood count during regular follow-up and in case of
metabolic decompensation, since anaemia, neutro-
penia and/or thrombocytopenia can be a complica-
tion in MMA and PA patients.
Outcome: Haematological complications.
Quality of evidence: moderate.
Strength of recommendation: weak.
3.4.5 | Bone health
Patients with MMA and PA are at risk of low bone den-
sity and osteoporosis,128,202,203 which may be aggravated
by kidney dysfunction in MMA. Risk factors for low bone
density and osteoporosis in MMA and PA patients can
include chronic acidosis (causing osteoclast activation
and osteoblast inhibition), impaired kidney function and
inadequate dietary intake of calcium, phosphate and vita-
min D. Further it has been hypothesised, that the appli-
cation of amino acid supplements can decrease bone
mineralisation, as it increases the load of extracted acids,
leading to buffering of protons in the bone tissue and
increased bone resorption.122 Optimisation of calcium
and phosphate intake and vitamin D supplementation




Plasma: NH3, acid base balance (via blood
gas analysisa), lactate; urine: ketones
Each clinic visit
Quantitative plasma amino acids (3-4 h of
fasting prior to sample collection)
3-6 monthly
Methylmalonic acid in plasma (and urine if
available)
3-6 monthly
Acylcarnitine profile in dried blood or
plasma (propionylcarnitine and free
carnitine)
3-6 monthly
Diet and nutritional status
Diet history Each clinic visit
Growth (weight, length or height, head
circumference)
Each clinic visitb
Full clinical examination Each clinic visit
Albumin, total protein, transferrin 6-monthly
Bone health (Ca, P, ALP, Mg, PTH, 25-OH
vitamin D in blood; Ca, P in urine)c
12-monthly




Neurological examination with assessment
of developmental milestones
Each clinic visit
Kidney function (blood pressure, serum
creatinine, electrolytes, cystatin C, uric
acid; urinary electrolytes and protein
loss; GFR)c,d
6-monthly
Pancreas function (lipase, pancreatic
amylase)
6-monthly





EEG, cerebral MRI When clinically
indicated
Ophthalmologic assessment 12-monthly
Formal hearing test When clinically
indicated
Abbreviations: ALP, alkaline phosphatase; Ca, calcium; ECG,
electrocardiogram; EEG, electroencephalogram; GFR, glomerular filtration
rate; Mg, magnesium; MRI, magnetic resonance imaging; P, phosphate; PA,
propionic acidaemia; PTH, parathyroid hormone.
aVenous or capillary blood sample.
abMore frequently in infants.
cMore frequently in the presence of chronic kidney disease.
dGFR: if available 12-monthly, alternatively use estimated GFR based on
cystatin C; in PA 12-monthly biochemistry is sufficient.
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The time and frequency of assessment of bone health
in MMA and PA should be guided by the risk of the indi-
vidual patient. If bone density measurements (dual-
energy X-ray absorptiometry [DEXA] scans) are applied
in growing children and adolescents, they should be com-
bined with assessment of bone age (and pubertal status)
for adequate interpretation of the results. Osteoporosis
can only be diagnosed in the presence of clinically signifi-
cant fracture history, which has only been scarcely
observed in MMA and PA.204 In patients with renal fail-
ure, the diagnosis of osteoporosis should only be made in
the absence of renal osteodystrophy.
For osteopenia or osteoporosis, treatment decisions
need to be individualised, integrating parameters of bone
metabolism, including secondary hyperparathyroidism in
patients with chronic renal failure. Once the diagnosis of
osteoporosis is established, treatment should follow com-
mon recommendations. Antiresorptive drugs (eg,
bisphosphonates) may be indicated in patients at
increased risk for fractures with relevant bone loss docu-
mented in serial DEXA measurements despite optimisa-
tion of nutritional support. The role of antiresorptive
drugs for treatment or prevention of osteoporosis has not
been systematically studied in MMA and PA patients.
Recommendation #18. We suggest assessment of bone
health, considering the risk of patients with MMA
and PA for impaired bone health.
Outcome: Bone health.
Quality of evidence: low.
Strength of recommendation: weak.
3.4.6 | Growth
Poor growth outcomes (weight, linear growth and head
circumference) are observed in MMA and PA
patients122,162,170,173,205,206 with a higher prevalence in
MMA.122 Lower birthweights compared to the normal
reference population are seen in newborns with MMA
but not in PA.207
Poor growth is more pronounced in mut0 and cblB
subtypes than cblA and mut− subtypes33,58,206 with no
reported difference between early and late-onset
patients.207 Linear growth appears more affected than
weight gain which can result in overweight and obesity
in MMA and PA patients.28,58,59,122,208 A high percentage
of fat mass is reported in MMA, particularly in mut0 and
cblB, 205,58 and PA patients.208 Failure to thrive was asso-
ciated with intellectual disability and increased mortality
in cobalamin non-responsive MMA patients.194 In MMA,
body length SD score decreased over time in patients
with movement disorders compared to those without.162
Linear growth improves in liver transplanted patients
with MMA, when protein intake was relaxed but not
unrestricted.101
The causes for poor growth are considered to be mul-
tifactorial. Nutritional reasons are commonly cited and
include over-restriction of natural protein,209-211 inade-
quate protein and energy intakes,212 use of
PFAAs,203,206,208,213,214 malnutrition secondary to feeding
difficulties206 and frequent hospitalisations for metabolic
decompensations preventing the usual diet and nutrients
intake.215 While total energy intake does not seem to cor-
relate with linear growth a protein to energy ratio of 1.5
to 2.9 g protein/100 kcal/day is positively correlated with
growth outcomes in patients with inborn errors of inter-
mediary protein metabolism.208
Use of PFAAs is common practice in some centres
with a variable prescription regarding percentage of total
protein intake.33,60,203,209-211,215 However, PFAAs are low
in valine and isoleucine but high in leucine content and
can result in low plasma isoleucine and valine levels and
iatrogenic amino acid deficiencies associated with
adverse growth outcomes.206 The height z-score seems
positively correlated with natural-protein-to-energy pre-
scription ratio and plasma L-valine and L-arginine levels,
while negatively associated with the amount of
PFAAs.214 Hence, PFAAs should not substitute for an
adequate provision of natural protein and the need for
PFAAs requires further review.206,208 It is common prac-
tice to monitor plasma amino acids on a regular basis
and adjust the dietary regimen accordingly.
Recommendation #19. We suggest regular monitoring
of anthropometric measurements in MMA and PA
patients, as growth outcomes can be poor.
Outcome: Normal growth.
Quality of evidence: moderate.
Strength of recommendation: weak.
Growth can potentially be improved after organ trans-
plantation, but persistent growth delay and even
decreased growth rate have also been
reported.44,80,81,97,100,102,104,106,118,216 Factors influencing
growth after transplantation need to be determined.
3.4.7 | Pancreatitis
Acute, recurrent acute and chronic pancreatitis are possi-
ble long-term complications of MMA32,122,217 and
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PA.13,23,28,122,205,218,219 Pancreatitis has been observed in
around 5% to 10% of patients13,122,205 and may develop
independently from metabolic decompensations and met-
abolic control.13,194 There is weak evidence that pancrea-
titis correlates with mortality.32,194
Like in individuals without MMA or PA, the clinical
presentation of pancreatitis is variable. It is of note that
pancreatitis can occur without abdominal pain and may
therefore be under-recognised.220,221
There is no evidence that management of acute or
chronic pancreatitis in MMA and PA has specific aspects
different from general standards on pancreatitis treat-
ment. Adequate energy supply should be maintained
throughout an episode of pancreatitis to ensure metabolic
stability.
Recommendation #20. We strongly recommend
prompt evaluation for pancreatitis in MMA and PA
patients if clinically suspected, since both acute and
chronic pancreatitis are known complications in
PA and MMA.
Outcome: Pancreatitis.
Quality of evidence: moderate.
Strength of recommendation: very strong.
3.5 | Health-related quality of life
HrQoL and psychological adjustment are meaningful
outcome parameters that should be considered in the
care for children with chronic disease.222,223 The high rat-
ing of the outcome HrQoL illustrates the importance of
this parameter to health professionals and experts as well
as patient representatives. In MMA and PA, HrQoL has
so far scarcely been systematically addressed.224 Most of
our knowledge on HrQoL in MMA and PA has been
extrapolated from studies in combined samples of
inherited metabolic disease patients applying generic or
chronic generic instruments. Only very few reports pre-
sent isolated data on HrQoL in PA or MMA patients.
HrQoL was addressed in 13 PA patients, using a
generic instrument (KINDL), and found significantly
lower HrQoL for the ‘psychological’ and ‘friends’
domain. Higher HrQoL was reported for the ‘school’
domain. Correlations with disease- or family-related
parameters or impact of interventions on HrQoL were
not investigated.28
For 35 MMA mut0 patients their parents or care-
givers completed the PedsQl generic core, transplant as
well as family impact modules proxy versions. They
reported lower mean PedsQl core scale scores (in com-
parison to healthy children) and lower scores on the
transplant scales (as compared to other indication
groups for liver transplantation). Compared to families
of children with other complex chronic conditions,
MMA families had a lower quality of life. Free com-
ments suggested a favourable effect of liver transplanta-
tion on HrQoL.225
Recently, Zeltner et al have developed a specific ques-
tionnaire for the assessment of HrQoL in intoxication-
type metabolic disorders.226 In contrast to generic instru-
ments, specific tools are tailor-made for disease groups
with patients participating in the process.227 Specific
instruments are more suitable to detect changes over
time or following interventions.
If considered, we strongly recommend systematic
assessment of HrQoL with standardised instruments. We
recommend choosing generic, chronic generic and/or
specific instruments in line with the question to be
addressed. While there is weak evidence suggesting that
MMA and PA patients and their families have impaired
HrQoL, there is not enough evidence to give recommen-
dations on interventions to improve HrQoL in MMA
and PA.
Recommendation #21. We recommend considering
health-related quality of life a relevant outcome
parameter in MMA and PA.
Outcome: Health-related quality of life.
Quality of evidence: moderate.
Strength of recommendation: strong.
3.6 | Monitoring
There is no strong evidence base as to when which moni-
toring investigations are indicated in MMA and PA
patients. The panel recommends a slightly modified mon-
itoring scheme compared to the initial guidelines
(Table 5), which can guide clinical management but
should be tailored to individual patients' needs. In addi-
tion to the items represented in the table, we recommend
regular contact to a metabolic dietitian. A full clinical
examination should be performed at each patient visit,
focusing on the cardiovascular system and neurological
aspects but also comprising an assessment of skin, nails
and hair as part of the nutritional assessment of the
patient.
4 | CONCLUDING REMARKS
This update of the MMA and PA guidelines provides a
digest of evaluated clinically relevant evidence published
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on these disorders. Based on the present evidence, 21 rec-
ommendations were formulated by a diverse panel of
metabolic disease health care professionals. It has to be
noted, though, that the participants predominantly had a
European/Mediterranean background. For a next revi-
sion, it is intended to overcome this limitation and form
a more heterogeneous panel. There remain significant
knowledge gaps regarding the optimal management of
MMA and PA patients. While more and better-quality
evidence is needed in the study of MMA and PA, we will
continue to evaluate the literature on a regular basis to
enable health care professionals working in the field to
make well-informed decisions, which are not based on
dogmatic expert knowledge.
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